Evotec SE (MIL:1EVT)
€ 8.345 0 (0%) Market Cap: 1.52 Bil Enterprise Value: 1.61 Bil PE Ratio: 0 PB Ratio: 1.56 GF Score: 54/100

Evotec SE Conference Call Transcript

May 10, 2023 / 12:00PM GMT
Werner Lanthaler
Evotec SE - Former Chairman of Management Board & CEO

Good morning, good afternoon. Welcome to Evotec. Today is an important day because it's a significant impact that will happen through the new partnership between Sandoz and Just-Evotec Biologics for the world. Why do I say this? Because when we think about access, then this partnership will make a huge contribution in the future. We have uploaded a presentation for this call that I will host together with Matthias Evers, who was pivotal to make this deal happen. When it comes to the presentation, I would like to guide you to Page #2, which gives you an overview of the tech partnership for biosimilars that we have initiated together with Sandoz.

Before that, let me start by a general definition of what a biosimilar is. The FDA defines a biosimilar is a biological product that is highly similar and has no clinically meaningful differences from an existing FDA-approved reference product. And these are differences when it comes to safety, purity and potency. That's a biosimilar. And I make this definition because typically

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot